Capecitabine and PPE syndrome: A case report [1]

Breast Journal

Volumn 9, Issue 1, 2003, Pages 64-65

  LoRusso, Patricia M ^a  

^a KARMANOS CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIUM LACTATE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; METHOTREXATE; PACLITAXEL; PYRIDOXINE; TAMOXIFEN;

ADULT; BONE MARROW TRANSPLANTATION; BONE METASTASIS; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CASE REPORT; DIARRHEA; DRUG WITHDRAWAL; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERPIGMENTATION; LETTER; NAUSEA; PROPHYLAXIS; SYMPTOMATOLOGY; VOMITING;

ANTIMETABOLITES, ANTINEOPLASTIC; BONE NEOPLASMS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; ERYTHEMA; FEMALE; FOOT; HAND; HUMANS; MIDDLE AGED; PARESTHESIA; TREATMENT OUTCOME;

EID: 0037266232     PISSN: 1075122X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4741.2003.09119.x     Document Type: Letter

References (6)

1. Blum JL. Xeloda in the treatment of metastatic breast cancer. Oncology 1999;57(suppl 1):16-20.
2. Frings S. Capecitabine - a novel oral tumor-activated fluoropyrimidine. Oncology 1998;21:451-58.
3. Dooley M, Goa KL. Capecitabine. Drugs 1999;58:69-76.
4. O'Shaughnessy J, Moiseyenko V, Bell D, et al. A randomized phase II study of Xeloda™ (capecitabine) vs CMF as first line chemotherapy for breast cancer in women aged 55 years. Proc Am Soc Clin Oncol 1998;17:103a.
5. Marty M, Espie M, Cottu PH, et al. Optimizing chemotherapy for patients with advanced breast cancer. Oncology 1999;57(suppl 1):21-26.
6. Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999;17:485-93.